Literature DB >> 30300585

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, Michael A Postow, Yasin Senbabaoglu, Sasikanth Manne, Billel Gasmi, Cailian Liu, Hong Zhong, Yanyun Li, Alexander C Huang, Daniel Hirschhorn-Cymerman, Katherine S Panageas, E John Wherry, Taha Merghoub, Jedd D Wolchok.   

Abstract

Entities:  

Year:  2018        PMID： 30300585      PMCID： PMC6656529          DOI： 10.1016/j.ccell.2018.09.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  9 in total

1.  LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.

Authors:  Ronglai Shen; Michael A Postow; Matthew Adamow; Arshi Arora; Margaret Hannum; Colleen Maher; Phillip Wong; Michael A Curran; Travis J Hollmann; Liwei Jia; Hikmat Al-Ahmadie; Niamh Keegan; Samuel A Funt; Gopa Iyer; Jonathan E Rosenberg; Dean F Bajorin; Paul B Chapman; Alexander N Shoushtari; Allison S Betof; Parisa Momtaz; Taha Merghoub; Jedd D Wolchok; Katherine S Panageas; Margaret K Callahan
Journal:  Sci Transl Med       Date:  2021-08-25       Impact factor: 19.319

2.  Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Authors:  James C Lee; Sadaf Mehdizadeh; Jennifer Smith; Arabella Young; Ilgiz A Mufazalov; Cody T Mowery; Adil Daud; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2020-10-02

Review 3.  Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.

Authors:  Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Gonzalo Fernandez; Luisa Chocarro; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

4.  Obesity diminishes response to PD-1-based immunotherapies in renal cancer.

Authors:  Shannon K Boi; Rachael M Orlandella; Justin Tyler Gibson; William James Turbitt; Gal Wald; Lewis Thomas; Claire Buchta Rosean; Katlyn E Norris; Megan Bing; Laura Bertrand; Brett P Gross; Amani Makkouk; Dmytro Starenki; Kristine I Farag; Robert E Sorge; James A Brown; Jennifer Gordetsky; Hesham Yasin; Rohan Garje; Lakshminarayanan Nandagopal; George J Weiner; David M Lubaroff; Rebecca C Arend; Peng Li; Yousef Zakharia; Eddy Yang; Aliasger K Salem; Kenneth Nepple; Tatiana T Marquez-Lago; Lyse A Norian
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 5.  Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.

Authors:  Allan Relecom; Maysaloun Merhi; Varghese Inchakalody; Shahab Uddin; Darawan Rinchai; Davide Bedognetti; Said Dermime
Journal:  J Exp Clin Cancer Res       Date:  2021-02-18

6.  Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.

Authors:  Xiaohan Ren; Xinglin Chen; Xu Zhang; Silin Jiang; Tongtong Zhang; Guangyao Li; Zhongwen Lu; Dong Zhang; Shangqian Wang; Chao Qin
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

7.  Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.

Authors:  Jesse J Lipp; Limei Wang; Haitang Yang; Feng Yao; Nathalie Harrer; Stefan Müller; Sabina Berezowska; Patrick Dorn; Thomas M Marti; Ralph A Schmid; Belazs Hegedüs; Abdallah Souabni; Sebastian Carotta; Mark A Pearson; Wolfgang Sommergruber; Greg J Kocher; Sean R R Hall
Journal:  Oncoimmunology       Date:  2022-02-09       Impact factor: 8.110

8.  Characterizing CDK12-Mutated Prostate Cancers.

Authors:  Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 13.801

Review 9.  Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors:  Valli De Re; Laura Caggiari; Ombretta Repetto; Lara Mussolin; Maurizio Mascarin
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.